CureVac BV, which is developing a messenger RNA (mRNA) vaccine for Covid-19, has appointed Franz-Werner Haas as chief executive and Igor Splawski as chief scientific officer. Both appointments come as the candidate vaccine progresses in the clinic. Dr Haas joined CureVac in June 2012 and recently was acting CEO. Before that, he was head of operations and compliance for SYGNIS Pharma AG, a specialty pharma company.
Dr Splawski joins the company from the Novartis Institutes for BioMedical Research where he was executive director of the Institute’s biologics center in Cambridge, US. Before that, he was an assistant professor at Harvard Medical School.
CureVac announced the appointments on 4 August 2020.
Copyright 2020 Evernow Publishing Ltd